NO156168C - Fremgangsmaate for fremstilling av den terapeutisk aktive krystallinske, hydratiserte form, betegnet "form d", av natriumsaltet av syn-isomer 3-acetoxymethyl-7-(2-(2-amino-4-thiazolyl)-2-methoxyimino-acetamido)-cef-3-em-4-carb. - Google Patents

Fremgangsmaate for fremstilling av den terapeutisk aktive krystallinske, hydratiserte form, betegnet "form d", av natriumsaltet av syn-isomer 3-acetoxymethyl-7-(2-(2-amino-4-thiazolyl)-2-methoxyimino-acetamido)-cef-3-em-4-carb.

Info

Publication number
NO156168C
NO156168C NO782782A NO782782A NO156168C NO 156168 C NO156168 C NO 156168C NO 782782 A NO782782 A NO 782782A NO 782782 A NO782782 A NO 782782A NO 156168 C NO156168 C NO 156168C
Authority
NO
Norway
Prior art keywords
2hyzolyl
hydratized
crystallinic
cef
acetoxymethyl
Prior art date
Application number
NO782782A
Other languages
English (en)
Norwegian (no)
Other versions
NO156168B (no
NO782782L (no
Inventor
Gaston Amiard
Jean Jolly
Dieter Bormann
Walter Duerckheimer
Original Assignee
Roussel Uclaf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9194564&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO156168(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Roussel Uclaf filed Critical Roussel Uclaf
Publication of NO782782L publication Critical patent/NO782782L/no
Publication of NO156168B publication Critical patent/NO156168B/no
Publication of NO156168C publication Critical patent/NO156168C/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14—Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
    • C07D501/26—Methylene radicals, substituted by oxygen atoms; Lactones thereof with the 2-carboxyl group
    • C07D501/34—Methylene radicals, substituted by oxygen atoms; Lactones thereof with the 2-carboxyl group with the 7-amino radical acylated by carboxylic acids containing hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cephalosporin Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO782782A 1977-08-17 1978-08-16 Fremgangsmaate for fremstilling av den terapeutisk aktive krystallinske, hydratiserte form, betegnet "form d", av natriumsaltet av syn-isomer 3-acetoxymethyl-7-(2-(2-amino-4-thiazolyl)-2-methoxyimino-acetamido)-cef-3-em-4-carb. NO156168C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR7725142A FR2400519A1 (fr) 1977-08-17 1977-08-17 Forme cristalline du sel de sodium d'un derive oximine de l'acide 7-amino-thiazolyl acetamido cephalosporanique, son procede de preparation et son application comme medicament

Publications (3)

Publication Number Publication Date
NO782782L NO782782L (no) 1979-02-20
NO156168B NO156168B (no) 1987-04-27
NO156168C true NO156168C (no) 1987-08-19

Family

ID=9194564

Family Applications (1)

Application Number Title Priority Date Filing Date
NO782782A NO156168C (no) 1977-08-17 1978-08-16 Fremgangsmaate for fremstilling av den terapeutisk aktive krystallinske, hydratiserte form, betegnet "form d", av natriumsaltet av syn-isomer 3-acetoxymethyl-7-(2-(2-amino-4-thiazolyl)-2-methoxyimino-acetamido)-cef-3-em-4-carb.

Country Status (34)

Country Link
US (1) US4224371A (xx)
EP (1) EP0001024B1 (xx)
JP (1) JPS5441890A (xx)
AT (2) AT366049B (xx)
AU (1) AU520898B2 (xx)
BG (2) BG33888A3 (xx)
CA (1) CA1121343A (xx)
CS (2) CS207646B2 (xx)
DD (1) DD137588A5 (xx)
DE (1) DE2860358D1 (xx)
DK (2) DK152213C (xx)
EG (1) EG13520A (xx)
ES (1) ES472381A1 (xx)
FI (1) FI65433C (xx)
FR (1) FR2400519A1 (xx)
GE (2) GEP19960475B (xx)
GR (1) GR73661B (xx)
HR (1) HRP931395B1 (xx)
HU (1) HU181497B (xx)
IE (1) IE47230B1 (xx)
IL (1) IL55186A (xx)
IT (1) IT1107961B (xx)
MD (2) MD225C2 (xx)
MX (2) MX155976A (xx)
NO (1) NO156168C (xx)
NZ (1) NZ188163A (xx)
OA (1) OA06016A (xx)
PL (1) PL126619B1 (xx)
PT (1) PT68431A (xx)
RO (1) RO79999A (xx)
SI (1) SI7811917A8 (xx)
SU (2) SU799666A3 (xx)
YU (1) YU42166B (xx)
ZA (1) ZA784187B (xx)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60120886A (ja) * 1983-12-02 1985-06-28 Takeda Chem Ind Ltd セフェムカルボン酸のナトリウム塩の結晶
DE3485860T2 (de) * 1983-12-29 1993-01-14 Mochida Pharm Co Ltd Cephalosporinverbindungen, verfahren zu ihrer herstellung und pharmazeutishe praeparate.
JPS60142987A (ja) * 1983-12-29 1985-07-29 Mochida Pharmaceut Co Ltd セフアロスポリン誘導体
US4840945A (en) * 1985-04-01 1989-06-20 Mochida Pharmaceutical Co., Ltd. Cephalosporin derivatives
ATE138664T1 (de) * 1985-08-12 1996-06-15 Upjohn Co Umwandlung des cephalosporin-hydrohalid-salzes zu einem alkalimetallsalz
US4880798A (en) * 1986-11-25 1989-11-14 Mochida Pharmaceutical Co., Ltd. Cephalosporin derivatives
JPS63132893A (ja) * 1986-11-25 1988-06-04 Mochida Pharmaceut Co Ltd 新規セフアロスポリン誘導体、その製法およびそれらを有効成分とする抗菌剤
RU2021274C1 (ru) 1991-05-17 1994-10-15 Польска Акадэмия Наук Институт Хэмии Органичнэй Способ получения аминотиазолильных производных цефалоспорина
US5318781A (en) * 1993-04-06 1994-06-07 Hoffmann-La Roche Inc. Absorption enhancement of antibiotics
US5574154A (en) * 1994-09-29 1996-11-12 Alnejma Bulk Pharmaceutical Co. A.B.P.C. Process for the preparation of cephalosporanic compounds
GB9423459D0 (en) * 1994-11-21 1995-01-11 Biochemie Gmbh Silylation process
AT402928B (de) * 1994-12-23 1997-09-25 Biochemie Gmbh Neues verfahren zur herstellung von cefotaxim
AU690482B2 (en) * 1996-03-18 1998-04-23 Ranbaxy Laboratories Limited Process for producing cephalosporin antibiotics
GB9717629D0 (en) * 1997-08-21 1997-10-22 Johnson Matthey Plc Removal of residual organic solvents
WO2001092254A1 (fr) * 2000-05-30 2001-12-06 Fujisawa Pharmaceutical Co., Ltd. Procede permettant de remplacer des solvants contenus dans des cristaux de type clathrates
WO2004063203A1 (en) * 2003-01-10 2004-07-29 Orchid Chemicals & Pharmaceuticals Ltd Process for the preparation of cefotaxime sodium
CN100361995C (zh) * 2004-10-27 2008-01-16 山东瑞阳制药有限公司 注射级无菌头孢噻肟钠的一步法制备工艺

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3970651A (en) * 1974-01-07 1976-07-20 Bristol-Myers Company Crystalline cephalosporin derivative
US3985747A (en) * 1974-05-24 1976-10-12 Bristol-Myers Company Crystalline sesquihydrate of 7-[D-α-amino-α-(p-hydroxyphenyl)acetamido]-3-(1,2,3-triazol-5-ylthiomethyl)-3-cephem-4-carboxylic acid
DK154939C (da) * 1974-12-19 1989-06-12 Takeda Chemical Industries Ltd Analogifremgangsmaade til fremstilling af thiazolylacetamido-cephemforbindelser eller farmaceutisk acceptable salte eller estere deraf
US4006138A (en) * 1975-04-11 1977-02-01 Eli Lilly And Company Crystalline form of sodium O-formylcefamandole
DE2760123C2 (de) * 1976-01-23 1986-04-30 Roussel-Uclaf, Paris 7-Aminothiazolyl-syn-oxyiminoacetamidocephalosporansäuren, ihre Herstellung und sie enthaltende pharmazeutische Zusammensetzungen
SE440655B (sv) * 1976-01-23 1985-08-12 Roussel Uclaf Sett att framstella nya oximderivat av 7-amino-tiazolyl-acetamido-cefalosporansyra

Also Published As

Publication number Publication date
JPS6145626B2 (xx) 1986-10-08
BG33888A3 (en) 1983-05-16
FR2400519A1 (fr) 1979-03-16
MX5448E (es) 1983-08-09
DE2860358D1 (en) 1981-03-12
FI65433C (fi) 1984-05-10
DK159786D0 (da) 1986-04-09
ES472381A1 (es) 1979-03-16
EP0001024A1 (fr) 1979-03-07
DD137588A5 (de) 1979-09-12
GEP19960475B (en) 1996-07-22
DK163514C (da) 1992-07-27
JPS5441890A (en) 1979-04-03
OA06016A (fr) 1981-06-30
NO156168B (no) 1987-04-27
IL55186A0 (en) 1978-09-29
YU42166B (en) 1988-06-30
AT366049B (de) 1982-03-10
IE47230B1 (en) 1984-01-25
IL55186A (en) 1981-07-31
NZ188163A (en) 1981-10-19
ATA563578A (de) 1981-07-15
SI7811917A8 (en) 1997-12-31
ATA52280A (de) 1981-07-15
BG33887A3 (en) 1983-05-16
PT68431A (fr) 1978-09-01
MD247B1 (ro) 1995-07-31
SU852175A3 (ru) 1981-07-30
AU3896578A (en) 1980-02-21
YU191778A (en) 1983-02-28
GEP19960476B (en) 1996-07-22
DK361078A (da) 1979-02-18
MD225C2 (ro) 1995-12-31
AT366050B (de) 1982-03-10
DK163514B (da) 1992-03-09
EP0001024B1 (fr) 1981-01-21
IT1107961B (it) 1985-12-02
EG13520A (en) 1982-03-31
ZA784187B (en) 1979-09-26
FI782494A (fi) 1979-02-18
DK152213C (da) 1988-07-11
IE781669L (en) 1979-02-17
GR73661B (xx) 1984-03-28
DK159786A (da) 1986-04-09
CS207646B2 (en) 1981-08-31
CS207647B2 (en) 1981-08-31
RO79999A (ro) 1982-10-11
CA1121343A (fr) 1982-04-06
HRP931395B1 (en) 1996-04-30
FI65433B (fi) 1984-01-31
MD225B1 (ro) 1995-06-30
MX155976A (es) 1988-06-06
US4224371A (en) 1980-09-23
AU520898B2 (en) 1982-03-04
PL209080A1 (pl) 1979-06-04
PL126619B1 (en) 1983-08-31
SU799666A3 (ru) 1981-01-23
FR2400519B1 (xx) 1980-05-16
IT7850648A0 (it) 1978-08-08
HU181497B (en) 1983-07-28
DK152213B (da) 1988-02-08
MD247C2 (ro) 1995-12-31
NO782782L (no) 1979-02-20

Similar Documents

Publication Publication Date Title
NO156168C (no) Fremgangsmaate for fremstilling av den terapeutisk aktive krystallinske, hydratiserte form, betegnet "form d", av natriumsaltet av syn-isomer 3-acetoxymethyl-7-(2-(2-amino-4-thiazolyl)-2-methoxyimino-acetamido)-cef-3-em-4-carb.
NO149102C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive trans-4-fenyl-1,2,3,4-tetrahydro-1-naftalenamin-derivater
NO161117C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive cefalosporinderivater.
NO158099C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive karbostyrilderivater.
NO162022C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive cefemderivater.
NO895086D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive heterocykliske forbindelser.
NO152215C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 4,5-diaryl-2-nitroimidazoler
NO853293L (no) Fremgangsmaate for fremstilling av terapeutisk aktive heterocykliske derivater.
NO156864C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive piperinderivater.
NO164097C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 2-(n-substituert-guanidino)-4-hetero-aryl-tiazol-derivater.
NO152129C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive omega-cyan-1, omega-difenyl-azaalkanderivater
NO153569C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive merkaptoacetyl-prolin-derivater.
NO156787C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive kinolonderivater.
NO164301C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive cefalosporinderivater.
NO153496C (no) Analogifremgangsmaate for fremstilling av fysiologisk aktive indolizin-derivater.
NO160079C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive cefem-derivater.
NO154054C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive hydroksypyrimidinderivater.
NO158739C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 2-piperazinopyrimidinderivater.
NO160512C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive karbostyrilderivater.
NO151660C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive imidazolderivater.
NO150158C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive 6,7-dimetoksyquinazolinderivater
NO154052C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive kinolon-derivater.
NO154795C (no) Analogifremgangsmaate ved fremstilling av terapeutisk virksomme 1,2,4-oxadiazolin-5-on-derivater.
IT7820912A0 (it) Procedimento per la preparazione di derivati di cefalosporina, e composti cosi' preparati.
NO152839C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive karbostyrilderivater.